Abstract: Process for the industrial synthesis of the compound of formula (I): Application to the synthesis of bivalent salts of ranelic acid and more especially strontium ranelate and its hydrates.
Abstract: The invention relates to the identification of a new peptide interacting with the anti-apoptotic proteins Bcl-2, Bcl-W and/or Bcl-XL, and also to screening methods allowing identification of modifiers of those interactions.
Type:
Grant
Filed:
August 4, 2004
Date of Patent:
December 2, 2008
Assignee:
Les Laboratories Servier
Inventors:
Olivier Geneste, John Hickman, Richard Bennett, Jean-Christophe Rain
Abstract: Alpha crystalline form of strontium ranelate of formula (I): characterized by its powder X-ray diffraction diagram and by a water content of from 22 to 24%. Medicinal products containing the same which are useful in the treatment of osteoporosis and arthrosis.
Abstract: A compound selected from those of formula (I): wherein: R3 represents a hydrogen atom, and R1 and R2 together with the carbon atoms carrying them form a benzene, naphthalene or quinoline ring structure, each of the ring structures being optionally substituted, or R1 represents a hydrogen atom, and R2 and R3 together with the carbon atoms carrying them form a benzene, naphthalene or quinoline ring structure, each of the ring structures being optionally substituted, n represents 1 or 2, —X— represents a group selected from —(CH2)m—O-Ak-, —(CH2)m—NR4-Ak-, —(CO)—NR4-Ak- and —(CH2)m—NR4-(CO)—, m represents an integer between 1 and 6 inclusive, Ak represents an optionally substituted alkylene chain, and R4 represents a hydrogen atom or an alkyl group, Ar represents an aryl or heteroaryl group, its enantiomers, diasteroisomers, and addition salts thereof with a pharmaceutically acceptable acid.
Type:
Grant
Filed:
March 29, 2006
Date of Patent:
October 28, 2008
Assignee:
Les Laboratoires Servier
Inventors:
Guillaume De Nanteuil, Bernard Portevin, Philippe Gloanec, Mark Millan, Jean-Claude Ortuno, Clotilde Mannoury La Cour, Alain Gobert
Abstract: Compounds of formula (I): wherein: X1 represents an atom or group selected from CR4aR4b, O, S(O)q1 and NR5, wherein R4a, R4b, q1 and R5 are as defined in the description, m1 represents zero or an integer from 1 to 4 inclusive, m2 represents an integer from 1 to 4 inclusive, n1 and n2, which may be identical or different, each represent an integer from 1 to 3 inclusive, R1 represents hydrogen or a group selected from carboxy, alkoxycarbonyl, optionally substituted carbamoyl and optionally substituted alkyl, R2 represents hydrogen or alkyl, Ak represents an optionally substituted alkylene chain, p represents zero, 1 or 2, R3 represents hydrogen or cyano, X2 and X3, which may be identical or different, each represent either S(O)q2, or CR6aR6b, wherein q2, R6a and R6b are as defined in the description, its optical isomers, where they exist, and its addition salts with a pharmaceutically acceptable acid. Medicinal products containing the same which are useful as DPP-IV inhibitors.
Type:
Grant
Filed:
May 18, 2005
Date of Patent:
October 21, 2008
Assignee:
Les Laboratoires Servier
Inventors:
Guillaume De Nanteuil, Alain Benoist, Murielle Combettes, Elizabeth Harley
Abstract: A compound selected from those of formula (I): Medicinal products containing the same which are useful in the treatment of disorders of the melatoninergic system.
Type:
Grant
Filed:
June 29, 2007
Date of Patent:
October 14, 2008
Assignee:
Les Laboratoires Servier
Inventors:
Said Yous, Basile Peres, Ahmed Sabaouni, Pascal Berthelot, Michael Spedding, Philippe Delagrange, Daniel-Henri Caignard, Mark Millan
Abstract: Compounds of formula (I): wherein: R1 represents hydrogen, a halogen or alkyl, R1a represents hydrogen or alkyl, R2 represents hydrogen, a halogen or hydroxy, A represents NR4, R3 represents hydrogen, alkyl or cycloalkyl, R4 represents hydrogen or alkyl, X is as defined in the description, their isomers, and also addition salts thereof. Medicinal products containing the same which are useful in treating disorders of the AMPA system.
Type:
Grant
Filed:
June 27, 2007
Date of Patent:
September 9, 2008
Assignee:
Les Laboratoires Servier
Inventors:
Patrice Desos, Alex Cordi, Pierre Lestage
Abstract: A compound selected from those of formula (I): wherein: n represents an integer from 1 to 6 inclusive, R1 and R2 represent a hydrogen atom, a (C1-C6)alkyl group or an aryl-(C1-C6)alkyl group, R3 and R4 represent a hydrogen atom or a (C1-C6)alkyl group, R5 and R6 represent a hydrogen atom or a (C1-C6)alkyl, halogen, hydroxy, (C1-C6)alkoxy, cyano, nitro, (C2-C6)acyl, (C1-C6)alkoxycarbonyl, (C1-C6)trihaloalkyl or (C1-C6)-trihaloalkoxy group or an optionally substituted amino group, R7 represents a hydrogen atom, a (C1-C6)alkyl group or an arylalkyl group, its enatiomers, diastereoisomers and additional salts thereof with a pharmaceutically acceptable acid or base. Medicinal products containing the same which are useful in the treatment of conditions requiring a specific nicotinic ligand of ?4?2 receptors.
Type:
Grant
Filed:
July 26, 2006
Date of Patent:
June 17, 2008
Assignee:
Les Laboratoires Servier
Inventors:
Solo Goldstein, Claude Guillonneau, Yves Charton, Brian Lockhart, Pierre Lestage
Abstract: The present invention provides an attenuated virus, which is derived from Modified Vaccinia Ankara virus and characterized by induction of protective immunity against a lethal vaccinia virus infection in a mouse, whereby the effective amount of the MVA-BN virus, or a derivative thereof, required to confer said immunity is less than the effective amount of MVA-575 required to render said mouse immune to a lethal vaccinia virus infection, and/or the MVA-BN virus, or a derivative thereof, induces at least substantially the same level of immunity in vaccinia virus prime/vaccina virus boost regimes when compared to DNA prime/vaccinia virus boost regimes. It further describes recombinant viruses derived from this virus and the use of the virus, or its recombinants, as a medicament or vaccine. A method is provided for inducing an immune response in individuals who may be immune-compromised, receiving antiviral therapy, or have a pre-existing immunity to the vaccine virus.
Type:
Grant
Filed:
August 5, 2005
Date of Patent:
June 10, 2008
Assignee:
Bavarian Nordic A/S
Inventors:
Paul Chaplin, Paul Howley, Christine Meisinger-Henschel
Abstract: A ?d-crystalline form of ivabradine hydrochloride of formula (I): characterised by its powder X-ray diffraction data. Medicinal products containing the same which are useful as bradycardics.
Abstract: A compound of formula (I): wherein: R1, R2, R3, R4 are defined in the description, its enantiomers, diastereoisomers, tautomers and also addition salts thereof with a pharmaceutically acceptable acid or base, and medicinal products containing the same which are useful as kinase modulators.
Type:
Grant
Filed:
November 4, 2003
Date of Patent:
April 22, 2008
Assignee:
Les Laboratoires Servier
Inventors:
Sylvain Rault, Jean-Charles Lancelot, Marina Kopp, Daniel-Henri Caignard, Bruno Pfeiffer, Pierre Renard
Abstract: A ?-Crystalline form of ivabradine of formula (I): characterised by its powder X-ray diffraction data. Medicinal products containing the same which are useful as bradycardics.
Abstract: A process for the synthesis of compounds of formula (I): wherein R represents a linear or branched (C1-C6)alkyl group. Application in the synthesis of perindopril and its pharmaceutically acceptable salts.
Abstract: A ?-Crystalline form of ivabradine hydrochloride of formula (I): characterised by its powder X-ray diffraction data. Medicinal products containing the same which are useful as bradycardics.
Abstract: A ?d-Crystalline form of ivabradine hydrochloride of formula (I): characterized by its powder X-ray diffraction data. Medicinal products containing the same which are useful as bradycardics.
Abstract: A ?d-Crystalline form of ivabradine hydrochloride of formula (I): characterised by its powder X-ray diffraction data. Medicinal products containing the same which are useful as bradycardics.
Abstract: Crystalline form V of the compound of formula (I): characterised by its powder X-ray diffraction diagram. Medicinal products containing the same which are useful in the treatment of melatoninergic disorders.
Abstract: A ?-crystalline form of ivabradine hydrochloride of formula (I): characterised by its powder X-ray diffraction data. Medicinal products containing the same which are useful as bradycardics.